Showing results (551-560 of 587) with videos related to

Sort By:
Pageof 59
The New England Journal of Medicine|January 10, 2024
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung CancerAlexander Drilon, D Ross Camidge, Jessica J Lin, et al.
Nature Genetics|September 8, 2015
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomasFrancois Le Loarer, Sarah Watson, Gaelle Pierron, et al.
The Lancet. Haematology|December 12, 2018
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational studyNicolas Delanoy, Jean-Marie Michot, Thibault Comont, et al.
Lung Cancer (Amsterdam, Netherlands)|October 23, 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatmentVivek Subbiah, Luis Paz-Ares, Benjamin Besse, et al.
The European Respiratory Journal|September 29, 2018
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trialGuy Meyer, Benjamin Besse, Hélène Doubre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2025
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2Pascale Tomasini, Yongsheng Wang, Yongsheng Li, et al.
JTO Clinical and Research Reports|February 16, 2023
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC RegistryGiannis Mountzios, David Planchard, Giulio Metro, et al.
Journal for Immunotherapy of Cancer|February 17, 2022
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinationsAlessio Cortellini, Biagio Ricciuti, Victor R Vaz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSASe-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway InhibitorsNaoual Menssouri, Loïc Poiraudeau, Carole Helissey, et al.
Pageof 59